Skip to main content
Figure 1 | Journal of Hematology & Oncology

Figure 1

From: Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity

Figure 1

CK2 expression and activity in AML cells. (A) Real-time quantitative PCR analysis of CK2α mRNA expression in a panel of AML cell lines (K562, HL-60, NB4, ML2) and in normal CD34+ hematopoietic stem cells. (B) Top: representative western blot analysis of CK2α protein expression in a panel of AML cell lines (K562, HL-60, NB4, ML2) and in normal CD34+ hematopoietic stem cells; bottom: corresponding densitometric analysis. (C) In vitro kinase assay measuring CK2 kinase activity against a synthetic peptide using cell lysates from AML cell lines and normal CD34+ hematopoietic stem cells. (D) Western blot analysis of CK2α expression in normal - or patient derived AML - peripheral blood or bone marrow cells. Thirty-one AML cases were divided according to the European Leukemia Net classification of risk groups in favourable, intermediate-I, intermediate-II and unfavourable. Immunoblots are shown on the upper panel while the corresponding densitometric analysis is shown on the lower panel.

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us